Ticker Details
AbCellera Biologics Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.23B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 3.57%
Avg Daily Range (30 D):	$0.34 | 5.50%
Avg Daily Range (90 D):	$0.21 | 4.13%

Institutional Daily Volume
Avg Daily Volume:	2.66M
Avg Daily Volume (30 D):	7.21M
Avg Daily Volume (90 D):	5.99M

Trade Size
Avg Trade Size (Sh.):	174
Avg Trade Size (Sh.) (30 D):	195
Avg Trade Size (Sh.) (90 D):	220

Institutional Trades
Total Institutional Trades:	1,449
Avg Institutional Trade:	$1.75M
Avg Institutional Trade (30 D):	$1.78M
Avg Institutional Trade (90 D):	$1.51M
Avg Institutional Trade Volume:	.18M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.9M
Avg Closing Trade (30 D):	$2.03M
Avg Closing Trade (90 D):	$1.52M
Avg Closing Volume:	203.93K

News

Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai

Jul 30, 2025 @ 5:00 PM Global Antibody Discovery Market to Observe Stupen... Source: Delveinsight

Jun 13, 2024 @ 9:40 AM Down 57%, Is AbCellera Biologics a Buy on the Dip?... Source: newsfeedback@fool.com (Cory Renauer)

May 8, 2024 @ 8:30 AM AbCellera Biologics (ABCL) Q1 2024 Earnings Call T... Source: newsfeedback@fool.com (Motley Fool Transcribing)

May 7, 2024 @ 10:05 PM AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, M... Source: Zacks Equity Research

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.48	$-.14	$-.03
Diluted EPS	$-.48	$-.14	$-.03
Revenue	$79.21M	$8.32M	$44.85M
Gross Profit
Net Income / Loss	$-143.96M	$-43.17M	$-8.95M
Operating Income / Loss	$-211.96M	$-57.52M	$-28.58M
Cost of Revenue
Net Cash Flow	$-82.76M	$-51.45M	$44.8M
PE Ratio